Virological reactivation of the hepatitis B virus after simplification of antiretroviral treatment.

Enferm Infecc Microbiol Clin (Engl Ed)Aug 14, 2026 (epub)
Case ReportInfectious DiseasesInternal Medicine (General)

Marta Segura Díaz, Sergio Ferra Murcia, Daniel Collado Díaz et al.

✦ AI-curated · Sources linked

Case in brief

Two patients living with HIV and isolated anti-HBc positivity experienced hepatitis B virus (HBV) reactivation after simplifying their antiretroviral therapy (ART) to regimens without anti-HBV activity. A 63-year-old woman had detectable HBV DNA at 659 IU/mL one month after starting cabotegravir/rilpivirine, while a 55-year-old man showed reactivation at 2626 IU/mL after switching to dolutegravir/rilpivirine. Both achieved viral suppression upon reintroduction of anti-HBV therapy.

Diagnostic / clinical pearl

Clinicians should be aware that simplifying ART regimens in patients with a history of HBV infection may lead to viral reactivation if anti-HBV agents are not included.

Source

PubMed · PMID 42601248

Published in Enferm Infecc Microbiol Clin (Engl Ed). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.